| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
101,390,000 |
| Market
Cap: |
1.64(B) |
| Last
Volume: |
668,805 |
Avg
Vol: |
666,964 |
| 52
Week Range: |
$12.32 - $16.78 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
215,000 |
664,000 |
| Total Buy Value |
$0 |
$0 |
$2,804,388 |
$8,468,005 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
5 |
12 |
| Total Shares Sold |
0 |
0 |
10,994 |
10,994 |
| Total Sell Value |
$0 |
$0 |
$153,810 |
$153,810 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ronsheim Matthew |
See Remarks |
• • – |
2024-05-20 |
4 |
D |
$16.13 |
$4,323 |
D/D |
(268) |
40,510 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• • – |
2024-05-20 |
4 |
D |
$16.13 |
$15,743 |
D/D |
(976) |
46,590 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2024-03-05 |
4 |
A |
$14.88 |
$159,990 |
D/D |
10,752 |
47,566 |
|
- |
|
| Basso Stephen |
Chief Financial Officer |
• – – |
2024-03-05 |
4 |
A |
$14.88 |
$179,988 |
D/D |
12,096 |
12,096 |
|
- |
|
| Ronsheim Matthew |
See Remarks |
• – – |
2024-03-05 |
4 |
A |
$14.88 |
$189,988 |
D/D |
12,768 |
40,778 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• – – |
2024-02-20 |
4 |
D |
$15.80 |
$45,220 |
D/D |
(2,862) |
36,814 |
|
- |
|
| Ronsheim Matthew |
See Remarks |
• – – |
2024-02-20 |
4 |
D |
$15.80 |
$12,751 |
D/D |
(807) |
28,010 |
|
- |
|
| Ronsheim Matthew |
See Remarks |
• • – |
2024-01-18 |
4 |
D |
$16.05 |
$25,680 |
D/D |
(1,600) |
28,817 |
|
- |
|
| Ronsheim Matthew |
See RemarksOfficer |
• – – |
2024-01-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,945 |
|
-1% |
|
| Zhen Marianne |
Chief Accounting Officer |
• • – |
2023-11-20 |
4 |
D |
$13.62 |
$10,678 |
D/D |
(784) |
39,676 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• • – |
2023-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
302 |
40,460 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• • – |
2023-11-15 |
4 |
S |
$13.97 |
$153,810 |
D/D |
(10,994) |
40,158 |
|
-10% |
|
| Zhen Marianne |
Chief Accounting Officer |
• • – |
2023-08-18 |
4 |
D |
$13.64 |
$10,707 |
D/D |
(785) |
51,152 |
|
- |
|
| Sarissa Capital Management Lp |
|
• • • |
2023-06-06 |
4 |
B |
$13.05 |
$104,384 |
I/I |
8,000 |
7,215,000 |
0.01 |
2% |
|
| Sarissa Capital Management Lp |
|
• • • |
2023-06-05 |
4 |
B |
$13.04 |
$91,297 |
I/I |
7,000 |
7,207,000 |
0.01 |
1% |
|
| Sarissa Capital Management Lp |
|
• • • |
2023-05-30 |
4 |
B |
$13.01 |
$1,560,648 |
I/I |
120,000 |
7,200,000 |
0.01 |
3% |
|
| Sarissa Capital Management Lp |
|
• • • |
2023-05-26 |
4 |
B |
$13.12 |
$393,729 |
I/I |
30,000 |
7,080,000 |
0.01 |
1% |
|
| Sarissa Capital Management Lp |
|
• • • |
2023-05-25 |
4 |
B |
$13.09 |
$654,330 |
I/I |
50,000 |
7,050,000 |
0.01 |
-0% |
|
| Schlesinger Sarah J. |
Director |
– • – |
2023-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
16,495 |
104,706 |
|
- |
|
| Dipaolo Mark |
Director |
– • – |
2023-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
16,495 |
104,706 |
|
- |
|
| Srivastava Sapna |
Director |
– • – |
2023-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
16,495 |
30,173 |
|
- |
|
| Birx Deborah |
Director |
– • – |
2023-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
16,495 |
58,984 |
|
- |
|
| Haimovitz Jules |
Director |
– • – |
2023-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
16,495 |
116,906 |
|
- |
|
| Kostas Odysseas D |
Director |
– • – |
2023-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
16,495 |
108,702 |
|
- |
|
| Zhen Marianne |
Chief Accounting Officer |
• • – |
2023-05-19 |
4 |
D |
$13.47 |
$10,560 |
D/D |
(784) |
51,937 |
|
- |
|
704 Records found
|
|
Page 1 of 29 |
|
|
0.02 (0.12%) 
